A recent study found that supplementation with Sabinsa’s patented curcumin extract Curcumin C3 Complex combined with the patented piperine BioPerine, supported liver function in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Photo © Shutterstock.com/ COLOA Studio
A study recently published in the Journal of Cellular Biochemistry1 found that supplementation with Sabinsa’s patented curcumin extract Curcumin C3 Complex combined with the patented piperine BioPerine, supported liver function in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD). A chronic liver condition that effects about 25% of the U.S. population, according to the American Liver Foundation, NAFLD has no approved pharmaceutical treatments, and is commonly associated with metabolic syndrome and cardiovascular diseases.
In the study, 70 subjects with ultrasound-determined NAFLD were randomized to either receive 500 mg of curcumin extract with 5 mg of piperine daily, or placebo for 12 weeks. Results showed that supplementation significantly reduced elevated liver function parameters including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, as well as cholesterol, low-density lipoprotein cholesterol, iron, hemoglobin, and increased total iron-binding capacity. Based on sonography, the supplement group also saw improved NAFLD severity, compared to placebo.
“We're encouraged by the researchers’ conclusion that combined supplementation of C3 Complex and BioPerine may provide a safe and viable method for curtailing the progress of NAFLD,” said Sabinsa founder Muhammed Majeed, PhD, in a press release.
1. Panahi Y et al. “Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial.” Journal of Cellular Biochemistry, vol. 120, no. 9 (2019): 15989-15996
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.